Ovarian function during and after treatment with the new progestagen Org 30659.

@article{Obruca2001OvarianFD,
  title={Ovarian function during and after treatment with the new progestagen Org 30659.},
  author={Andreas Obruca and Tjeerd Korver and Johannes Huber and Stephen R Killick and B M Landgren and M J Struijs},
  journal={Fertility and sterility},
  year={2001},
  volume={76 1},
  pages={108-15}
}
OBJECTIVE To evaluate ovarian function during 21 days of oral administration of different doses of Org 30659, a novel selective progestagenic steroid. DESIGN Randomized, double-blind, dose-finding study. SETTINGS Three centers in Austria, Sweden, and the United Kingdom. PARTICIPANTS Eighty-one healthy women 19-40 years of age with regular ovulatory cycles. INTERVENTION Daily oral administration of 0.060, 0.120, 0.180, or 0.240 mg of Org 30659, or 0.075 mg desogestrel (reference group… CONTINUE READING